DGAP-News

Sangui BioTech, ECCPS and TransMIT start biological in vitro experiments aimed at the characterization of hemoglobin polymers

DGAP-News: Sangui BioTech International Inc. / Key word(s):
Miscellaneous
Sangui BioTech, ECCPS and TransMIT start biological in vitro
experiments aimed at the characterization of hemoglobin polymers

25.04.2014 / 13:00

---------------------------------------------------------------------

Sangui, ECCPS and TransMIT start biological in vitro experiments aimed at
the characterization of hemoglobin polymers

Witten, Germany, April 25, 2014

Staff members of the Excellence Cluster Cardio-Pulmonary System (ECCPS)
have started to carry out in vitro experiments aimed at the biological
characterization of Sangui's artificial oxygen carrier (hemoglobin
hyperpolymers) in laboratories of Giessen University. Target of the tests
are the effects of hemoglobin polymers on the blood pressure in freshly
isolated ex vivo perfused and ventilated lungs of mice. Native hemoglobin
(positive control) and an aqueous colloid/electrolyte solution without
hemoglobin (negative control) will serve as comparison perfusion media. All
test batches containing hemoglobin are being produced in the Sangui
laboratories in Witten, Germany. SanguiBioTech GmbH scientists are
accompanying the test series.

Native hemoglobin in the blood plasm generates hypertension, as it effects
a constriction of the arteries and arterioles of the blood vessel system.
This happens because it permeates the endothelium of the vessels,
thereunder it binds (and thus removes) a messenger substance that serves to
relax the blood vessels. Sangui assumes that the hemoglobin hyperpolymers
developed by the company are too big to permeate the vascular endothelium.
Therefore, they will not induce hypertension or only to a negligible
degree. This property is an important precondition for the successful
application of a blood additive.

In the meantime TransMIT Gesellschaft für Technologietransfer mbH, which is
involved in carrying out the project as co-contractor, has informed
SanguiBioTech GmbH that due to changes in the formalities required for the
appointment of animal protection officers recently imposed by the district
president which had to be adopted beforehand by TransMIT, regrettable
delays had occurred in the approval process of the animal tests applied for
by Sangui. The district president boards in charge of approvals are
expected to consult about the application in the course of the month of May
2014.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]


End of financial news

---------------------------------------------------------------------

25.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


264673 25.04.2014